TenX Keane Acquisition closes $66M IPO; $67.3M placed in trust for business combination

CITIUS ONCOLOGY, INC.

IPO of 6,600,000 units at $10/unit (including 600,000 over-allotment units) for gross proceeds of $66,000,000.
Private placement of 394,000 placement units to sponsor at $10/unit, raising additional $3,940,000.
Total $67,320,000 deposited into trust account for the benefit of public shareholders.
Units trade on Nasdaq as TENKU; shares as TENK; rights as TENKR.
Maxim Group LLC acted as sole book-running manager; IPO closed October 18, 2022.

item 1.01 item 3.02 item 5.03 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.